Predicting Recurrence and Progression in Patients with Non-Muscle-Invasive Bladder Cancer : Systematic Review on the Performance of Risk Stratification Models
Guerrero-Ramos, F. (Hospital Universitario 12 de Octubre (Madrid). Servicio de Urología)
Subiela, J.D. (Hospital Universitario Ramón y Cajal (Madrid))
Rodríguez Faba, Óscar (Institut d'Investigació Biomèdica Sant Pau)
Aumatell, Julia (Fundació Puigvert. Servicio de Urología)
Manfredi, Celeste (Unit Of Urology. Department Of Woman. Child And General And Specialized Surgery. University Of Campania 'Luigi Vanvitelli')
Bozzini, Giorgia (Department Of Urology. Asst Lariana Ospedale Sant'Anna)
Romero-Otero, Javier (Department Of Urology. Hospital Universitario Hm Sanchinarro)
Couñago, Felipe (Hospital La Milagrosa)

Data:	2022
Resum:	BACKGROUND: Several classifications have been reported to stratify non-muscle-invasive bladder cancer (NMIBC) in risk groups according to the probability of recurrence and progression. OBJECTIVE: To systematically review the current evidence regarding risk stratification of NMIBC. METHODS: The systematic review was performed in accordance with the PRISMA statement. Studies providing data on development and/or external validation cohorts of models and risk stratification tables for recurrence and/or progression for patients with NMIBC, reporting at least one discrimination measure (AUC or C-Index) were included. RESULTS: Twenty-five studies involving 22,737 patients were included. Six classifications were identified, three of them were predictive models (EORTC, CUETO, EAU 2021) and three were based on expert opinion (EAU 2020, AUA, NCCN). A high risk of bias was present in the majority of the studies. Certain heterogenicity was found among the studies regarding adjuvant therapy, postoperative instillation or second resection. The definition of oncological outcomes was not standardized in the included studies. CUETO and EORTC scoring systems are the most validated. In general, validations showed a poor discrimination capability to predict recurrence, slightly better for progression. The EAU 2021 model overestimates the risk of progression in patients treated with BCG. Carcinoma in situ is underrepresented in all the studies analyzed. CONCLUSIONS: The existing classifications show poor discrimination capability for recurrence and possibly helpful discrimination capability for progression in NMIBC patients. These results highlight the unmet need to develop novel accurate risk models for patients with NMIBC, which could be improved with the combination of clinicopathological and molecular information.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article de revisió ; recerca ; Versió publicada
Matèria:	Bladder cancer ; Recurrence ; Progression ; Risk stratification ; Systematic review ; Scoring ; Survival ; Calculator
Publicat a:	Bladder Cancer, Vol. 8 Núm. 4 (2022) , p. 339-357, ISSN 2352-3735

DOI: 10.3233/BLC-220055

19 p, 1.1 MB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut de Recerca Sant Pau
Articles > Articles de recerca
Articles > Articles publicats